Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe - PubMed (original) (raw)
Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe
Michel Warny et al. Lancet. 2005 Sep.
Abstract
Background: Toxins A and B are the primary virulence factors of Clostridium difficile. Since 2002, an epidemic of C difficile-associated disease with increased morbidity and mortality has been present in Quebec province, Canada. We characterised the dominant strain of this epidemic to determine whether it produces higher amounts of toxins A and B than those produced by non-epidemic strains.
Methods: We obtained isolates from 124 patients from Centre Hospitalier Universitaire de Sherbrooke in Quebec. Additional isolates from the USA, Canada, and the UK were included to increase the genetic diversity of the toxinotypes tested. Isolate characterisation included toxinotyping, pulsed-field gel electrophoresis (PFGE), PCR ribotyping, detection of a binary toxin gene, and detection of deletions in a putative negative regulator for toxins A and B (tcdC). By use of an enzyme-linked immunoassay, we measured the in-vitro production of toxins A and B by epidemic strain and non-dominant strain isolates.
Findings: The epidemic strain was characterised as toxinotype III, North American PFGE type 1, and PCR-ribotype 027 (NAP1/027). This strain carried the binary toxin gene cdtB and an 18-bp deletion in tcdC. We isolated this strain from 72 patients with C difficile-associated disease (58 [67%] of 86 with health-care-associated disease; 14 [37%] of 38 with community-acquired disease). Peak median (IQR) toxin A and toxin B concentrations produced in vitro by NAP1/027 were 16 and 23 times higher, respectively, than those measured in isolates representing 12 different PFGE types, known as toxinotype 0 (toxin A, median 848 microg/L [IQR 504-1022] vs 54 microg/L [23-203]; toxin B, 180 microg/L [137-210] vs 8 microg/L [5-25]; p<0.0001 for both toxins).
Interpretation: The severity of C difficile-associated disease caused by NAP1/027 could result from hyperproduction of toxins A and B. Dissemination of this strain in North America and Europe could lead to important changes in the epidemiology of C difficile-associated disease.
Comment in
- Outbreak from a high-toxin intruder: Clostridium difficile.
Norén T. Norén T. Lancet. 2005 Sep 24-30;366(9491):1053-4. doi: 10.1016/S0140-6736(05)67400-4. Lancet. 2005. PMID: 16182878 No abstract available. - Measurement of toxin production by Clostridium difficile.
Freeman J, Fawley W, Baines S, Wilcox M. Freeman J, et al. Lancet. 2006 Mar 25;367(9515):982-3; author reply 983-4. doi: 10.1016/S0140-6736(06)68417-1. Lancet. 2006. PMID: 16564352 No abstract available. - Clostridium difficile: more and meaner.
Oldfield EC 3rd. Oldfield EC 3rd. Rev Gastroenterol Disord. 2006 Summer;6(3):197-8. Rev Gastroenterol Disord. 2006. PMID: 16972351 No abstract available.
Similar articles
- An epidemic, toxin gene-variant strain of Clostridium difficile.
McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. McDonald LC, et al. N Engl J Med. 2005 Dec 8;353(23):2433-41. doi: 10.1056/NEJMoa051590. Epub 2005 Dec 1. N Engl J Med. 2005. PMID: 16322603 - First report of Clostridium difficile NAP1/027 in a Mexican hospital.
Camacho-Ortiz A, López-Barrera D, Hernández-García R, Galván-De Los Santos AM, Flores-Treviño SM, Llaca-Díaz JM, Maldonado-Garza HJ, Bosques-Padilla FJ, Garza-González E. Camacho-Ortiz A, et al. PLoS One. 2015 Apr 27;10(4):e0122627. doi: 10.1371/journal.pone.0122627. eCollection 2015. PLoS One. 2015. PMID: 25915544 Free PMC article. - Detection of virulence genes of Clostridium difficile by multiplex PCR.
Antikainen J, Pasanen T, Mero S, Tarkka E, Kirveskari J, Kotila S, Mentula S, Könönen E, Virolainen-Julkunen AR, Vaara M, Tissari P. Antikainen J, et al. APMIS. 2009 Aug;117(8):607-13. doi: 10.1111/j.1600-0463.2009.02509.x. APMIS. 2009. PMID: 19664132 - Emergence of Clostridium difficile-associated disease in North America and Europe.
Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Kuijper EJ, et al. Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18. doi: 10.1111/j.1469-0691.2006.01580.x. Clin Microbiol Infect. 2006. PMID: 16965399 Review. - New trends in Clostridium difficile virulence and pathogenesis.
Denève C, Janoir C, Poilane I, Fantinato C, Collignon A. Denève C, et al. Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S24-8. doi: 10.1016/S0924-8579(09)70012-3. Int J Antimicrob Agents. 2009. PMID: 19303565 Review.
Cited by
- Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment.
Spigaglia P. Spigaglia P. Pathogens. 2024 Jul 31;13(8):646. doi: 10.3390/pathogens13080646. Pathogens. 2024. PMID: 39204246 Free PMC article. Review. - Gut dysbiosis contributes to the development of Budd-Chiari syndrome through immune imbalance.
Lu Q, Zhu R, Zhou L, Zhang R, Li Z, Xu P, Wang Z, Wu G, Ren J, Jiao D, Song Y, Li J, Wang W, Liang R, Ma X, Sun Y. Lu Q, et al. mSystems. 2024 Sep 17;9(9):e0079424. doi: 10.1128/msystems.00794-24. Epub 2024 Aug 21. mSystems. 2024. PMID: 39166878 Free PMC article. - Encapsulation protocol for fecal microbiota transplantation.
Sipos D, Varga A, Kappéter Á, Halda-Kiss B, Kása P, Pál S, Kocsis B, Péterfi Z. Sipos D, et al. Front Cell Infect Microbiol. 2024 Jun 26;14:1424376. doi: 10.3389/fcimb.2024.1424376. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38988813 Free PMC article. - Genomic and phenotypic studies among Clostridioides difficile isolates show a high prevalence of clade 2 and great diversity in clinical isolates from Mexican adults and children with healthcare-associated diarrhea.
Meléndez-Sánchez D, Hernández L, Ares M, Méndez Tenorio A, Flores-Luna L, Torres J, Camorlinga-Ponce M. Meléndez-Sánchez D, et al. Microbiol Spectr. 2024 Jul 2;12(7):e0394723. doi: 10.1128/spectrum.03947-23. Epub 2024 Jun 12. Microbiol Spectr. 2024. PMID: 38864670 Free PMC article. - Contribution of MALDI-TOF mass spectrometry and machine learning including deep learning techniques for the detection of virulence factors of Clostridioides difficile strains.
Godmer A, Giai Gianetto Q, Le Neindre K, Latapy V, Bastide M, Ehmig M, Lalande V, Veziris N, Aubry A, Barbut F, Eckert C. Godmer A, et al. Microb Biotechnol. 2024 Jun;17(6):e14478. doi: 10.1111/1751-7915.14478. Microb Biotechnol. 2024. PMID: 38850267 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical